Clade c hiv-1 envelope (env) trimer immunogens, compositions including the clade c hiv-1 envelope (env) trimer immunogens, and uses thereof
AssigneesNova Southeastern University, The Forsyth Institute
InventorsMark J. Cayabyab, Alexander Bontempo
Life of this patent
Estimating the term…
Abstract
The invention encompasses a non-naturally occurring clade C human immunodeficiency virus type-1 (HIV-1) 1086.C envelope (ENV) SOSIP trimer protein. This trimer protein contains broadly neutralizing epitopes and epitopes that induce anti-V1/V2 antibodies and thus is an immunogen for creation of HIV-1 vaccines. The invention also includes prophylactic or therapeutic vaccine compositions/kits and methods for using the trimer protein as a component of a vaccine against HIV-1 infection.
Claims21
1-31. (canceled)
A trimer, wherein the trimer is a non-naturally occurring clade C human immunodeficiency virus type-1 (HIV-1) 1086.c envelope (ENV) trimer having a form stabilized with a disulfide SOSIP mutation and having a mutation that replaces an isoleucine residue at position 559 with a proline residue.
An immunogenic composition for eliciting an immune reaction in cells against clade C human immunodeficiency virus type-1 (HIV-1), the immunogenic composition comprising:
- a non-naturally occurring clade C human immunodeficiency virus type-1 (HIV-1) 1086.c envelope (ENV) trimer having a form stabilized with a disulfide SOSIP mutation and having a mutation that replaces an isoleucine residue at position 559 with a proline residue;
- and
- at least one of an adjuvant and a pharmaceutically acceptable carrier.
A method for inducing an immune response against clade C human immunodeficiency virus type-1 (HIV-1) infection in a subject in need thereof, the method comprising:
- providing a composition comprising a non-naturally occurring clade C human immunodeficiency virus type-1 (HIV-1) 1086.C envelope (ENV) trimer having a form stabilized with a disulfide SOSIP mutation and having a mutation that replaces an isoleucine residue at position 559 with a proline residue, and at least one of a pharmaceutically acceptable carrier, an adjuvant, and an HIV-1 envelope (ENV) trimer from a clade type other than clade C;
- and
- administering the composition to the subject.
Dependencies are inferred from the claim text.